

Survival (%)
100
80
60
40
20
0
0
5
10
15
20
25
30
35
Day Post-Tumor Cell Implantation
Vehicle
1.0 x 105 Cells
2.5 x 105 Cells
5.0 x 105 Cells

FIGURE 1



Vehicle
lapatinib 50 mg/kg, BID, PO
ARRY-380 75 mg/kg, BID, PO
ARRY-380
lapatanib
vehicle
Percent survival
150
100
50
0
0
10
20
30
40
50
Days

FIGURE 2




FIGURE 3



PLASMA
Plasma Concentration
Mean ± SD
10000
8000
6000
4000
2000
0
Time Point (hr)
0.5
1
2
4
AR00440993
ARRY-380
Lapatanib

FIGURE 4



BRAIN
Brain Concentration (ng/g)
Mean + SD
200
150
100
50
0
Time Point (hr)
0.5
1
2
4
AR00440993
ARRY-380
Lapatanib
AR00440993
ARRY-380
Lapatanib
AR00440993
ARRY-380
Lapatanib
AR00440993
ARRY-380
Lapatanib

FIGURE 5



Survival (%)
100
80
60
40
20
0
0
5
10
15
20
25
30
35
40
45
50
55
60
65
Day Post-Tumor Cell Implantation
ARRY-380
neratanib
vehicle
lapatanib
Vehicle
Lapatinib (50 mg/kg, BID, PO)
Neratinib (40 mg/kg, QD, PO)
ARRY-380 (75 mg/kg, BID, PO)

FIGURE 6



Tumor Volume (mm³)
900
800
700
600
500
400
300
200
100
0
0
5
10
15
20
25
Treatment Day
Vehicle
ARRY-380 50 mg/kg, QD, PO
ARRY-380 100 mg/kg, QD, PO
lapatinib 50 mg/kg, BID, PO
lapatinib 100 mg/kg, BID, PO
Vehicle
lapatanib (50 mg/kg)
ARRY-380 (50 mg/kg)
lapatanib (100 mg/kg)
ARRY-380 (100 mg/kg)

FIGURE 7